CAH vs MRK: fair value comparison
Cardinal Health, Inc. and Merck & Co., Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CAH currently sits closer to the top of our discount ranking. MRK carries the stronger quality grade.
| CAH | MRK | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $234.55 | $148.35 |
| 12-month range | $149.55–$235.60 | $82.49–$130.20 |
| Sector rank | #92 of 113 Healthcare | #95 of 113 Healthcare |
| Quality grade | F | C |
| Momentum grade | A | A |
| Leverage | Low | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Overvalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CAH fair value analysis · MRK fair value analysis